As the battle against cancer continues, new treatments and therapies are being developed to combat this deadly disease. Parthenon Therapeutics is one such company that is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME) to fight cancer. In this Startup Showcase, we will explore the innovative approach of Parthenon Therapeutics and how they are making strides in the biotech industry.
The Need for a New Class of Anti-Cancer Therapies
The interplay between cancer cells and their surrounding microenvironment is relevant in drug development, as many cancers use the TME to build barriers that shield them from the immune system attack. Traditional cancer therapies target cancer cells directly, but they often have limited success due to the protective mechanisms of the TME. Parthenon Therapeutics recognized the need for a new approach that would reprogram the TME to make it more susceptible to treatment.
Reprogramming the Tumor Microenvironment with PRTH-101
Parthenon Therapeutics is developing a drug candidate called PRTH-101, which breaks down the barriers in the TME and enables the immune system to attack the cancer cells. The drug candidate has shown promising results in preclinical studies, and the company is now preparing to move to clinical trials. The goal is to develop a drug that can be used in combination with existing therapies to overcome recalcitrant cancers.
Designing a Portfolio of Drug Candidates to Treat the Right Patients at the Right Time
Parthenon Therapeutics is not stopping with PRTH-101. Based on research, the company is designing a portfolio of drug candidates that will target specific types of cancer and specific patient populations. This personalized approach to cancer treatment has the potential to improve outcomes and reduce the side effects associated with traditional cancer treatments.
Location and Social Media Presence
Parthenon Therapeutics is located in Cambridge, Massachusetts, United States, which is home to many biotech and pharmaceutical companies. The company’s website provides detailed information on their research, team, and approach. They can also be found on LinkedIn, where they share updates on their progress and milestones.
Parthenon Therapeutics is a biotech company with an innovative approach to fighting cancer. By reprogramming the TME, the company is developing a new class of anti-cancer therapies that have the potential to improve outcomes and reduce the side effects of traditional cancer treatments. With their portfolio of drug candidates, Parthenon Therapeutics is poised to make a significant impact in the fight against cancer.